A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

NCT04594369 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1767

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Cystic Fibrosis Bronchiectasis

Interventions

DRUG: Brensocatib 10 mg
DRUG: Brensocatib 25 mg
DRUG: Placebo

Sponsor

Insmed Incorporated